Chronic Lymphocytic Leukemia Coverage from Every Angle
ABOUT
SECTIONS
JNCCN Spotlights
Videos
News
Medical Literature
CE Activities
Clinical Trials
For Your Patients
NCCN RESOURCES
NCCN Guidelines
®
NCCN Compendium
®
NCCN Templates
®
NCCN Guidelines for Patients®
360 HUB
Breast Cancer
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Colorectal Cancer
Head and Neck Cancers
Immunotherapy
Kidney Cancer
Melanoma
Multiple Myeloma
Non-Melanoma Skin Cancers
Non-Small Cell Lung Cancer
Ovarian Cancer
Prostate Cancer
JNCCN
Editor:
Jennifer R. Brown, MD, PhD
Advertisement
Advertisement
Published Medical Literature
Addition of Ibrutinib to Initial Treatment for Younger Patients With CLL
Long-Term Study Confirms Benefit of Idelalisib in Relapsed CLL
Do Ibrutinib Dose Modifications Affect Long-Term Benefits in CLL?
Natural Killer Cell Function Activated by CD19-Targeted Molecule in CLL
Suboptimal Dosing of Ibrutinib in Patients With CLL
Minimal Residual Disease Status and Long-Term Survival in CLL
Potential of Nitrostyrene Compounds in CLL
Do Risks Outweigh Benefits for Use of Idelalisib Plus Ofatumumab in CLL?
JNCCN Spotlights
?
Venetoclax
View More >
Advertisement
Resources
For your Patients
NCCN Guidelines for Patients®
Cancer.gov
Leukemia & Lymphoma Society
UpToDate
Copyright ©
2019
National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our
Privacy Policy
to learn more.
Bots not welcome here
